Complement and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 3, 2013, Pages 295-301

  Cook, H Terence ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C3 glomerulopathy; CFHR; Complement; Eculizumab

Indexed keywords

COMPLEMENT; COMPLEMENT FACTOR; ECULIZUMAB;

ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT COMPONENT C3 GLOMERULOPATHY; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY; KIDNEY DISEASES; MUTATION; PHENOTYPE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84878883523     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835ff9cb     Document Type: Review

References (51)

1. Lesher AM, Song WC. Review: complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010; 15:663-675.
2. Fakhouri F, Fremeaux-Bacchi V, Noel LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494-499.
3. Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20:271-277.
4. Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454-464.
5. Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465-473.
6. Malik TH, Lavin PJ, Goicoechea de JE, et al. A Hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23:1155-1160.
7. Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794-801.
8. Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436-1446.
9. Lu DF, Moon M, Lanning LD, et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 2012; 27:773-781.
10. Zhang Y, Meyer NC, Wang K, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012; 7:265-274.
11. Vernon KA, Goicoechea de JE, Hall AE, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 2012; 60:121-125.
12. Sandhu G, Bansal A, Ranade A, et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis 2012; 60:1039-1043.
13. Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83:293-299.
14. Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22-32.
15. Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56:977-982.
16. Bridoux F, Desport E, Fremeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011; 6:2165-2174.
17. Vernon KA, Pickering MC, Cook T. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease. Contrib Nephrol 2011; 169:198-210.
18. Ruseva MM, Vernon KA, Lesher AM, et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 2013; 24:43-52.
19. Lesher AM, Zhou L, Kimura Y, et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol 2013; 24:53-65.
20. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
21. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23:1229-1237.
22. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366:1161-1163.
23. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366:1163-1165.
24. Sargsyan SA, Serkova NJ, Renner B, et al. Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int 2012; 81:152-159.
25. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657.
26. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119:4182-4191.
27. Sartz L, Olin AI, Kristoffersson AC, et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012; 188:2030-2037.
28. Tortajada A, Pinto S, Martinez-Ara J, et al. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012; 81:56-63.
29. Turnberg D, Cook HT. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens 2005; 14:223-228.
30. Vernon KA, Cook HT. Complement in glomerular disease. Adv Chronic Kidney Dis 2012; 19:84-92.
31. Thurman JM, Tchepeleva SN, Haas M, et al. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol 2012; 302:F1529-F1536.
32. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 2011; 49:317-323.
33. Sekine H, Kinser TT, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011; 63:1076-1085.
34. Zhao J, Wu H, KhosraviM, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7:e1002079.
35. Alexander JJ, Chaves L, Chang A, Quigg RJ. The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int 2012; 82:961-968.
36. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012; 18:1401-1406.
37. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170:52-64.
38. Gou SJ, Yuan J, Chen M, et al. Circulating complement activation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013; 83:129-137.
39. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43:321-327.
40. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy:GWASreplication study and geospatial risk analysis. PLoS Genet 2012; 8:e1002765.
41. Hughes AE, Orr N, Esfandiary H, et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006; 38:1173-1177.
42. Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 1999; 14:881-886.
43. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17:1724-1734.
44. Espinosa M, Ortega R, Gomez-Carrasco JM, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 2009; 24:886-891.
45. Liu LL, Jiang Y, Wang LN, Liu N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol 2012; 169:148-155.
46. Kim SJ, Koo HM, Lim BJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One 2012; 7:e40495.
47. Onda K, Ohsawa I, Ohi H, et al. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol 2011; 12:64.
48. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105:1363-1371.
49. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemiareperfusion injury. J Am Soc Nephrol 2012; 23:1474-1485.
50. van der Pol P, Schlagwein N, van Gijlswijk DJ, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant 2012; 12:877-887.
51. Renner B, Ferreira VP, Cortes C, et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 2011; 80:165-173.